Literature DB >> 36104488

Two-drug trick to target the brain blocks toxicity in the body.

Matthias P Wymann, Chiara Borsari.   

Abstract

Entities:  

Keywords:  Chemical biology

Mesh：

Year:  2022        PMID： 36104488     DOI： 10.1038/d41586-022-02892-5

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   69.504


× No keyword cloud information.
  10 in total

1.  Synthesis of calcineurin-resistant derivatives of FK506 and selection of compensatory receptors.

Authors:  Paul A Clemons; Brian G Gladstone; Abhinav Seth; Elizabeth D Chao; Michael A Foley; Stuart L Schreiber
Journal:  Chem Biol       Date:  2002-01

2.  Characterization of the FKBP.rapamycin.FRB ternary complex.

Authors:  Laura A Banaszynski; Corey W Liu; Thomas J Wandless
Journal:  J Am Chem Soc       Date:  2005-04-06       Impact factor: 15.419

3.  Inhibition of calcineurin by a novel FK-506-binding protein.

Authors:  T J Sewell; E Lam; M M Martin; J Leszyk; J Weidner; J Calaycay; P Griffin; H Williams; S Hung; J Cryan
Journal:  J Biol Chem       Date:  1994-08-19       Impact factor: 5.157

4.  Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery.

Authors:  Travis T Wager; Xinjun Hou; Patrick R Verhoest; Anabella Villalobos
Journal:  ACS Chem Neurosci       Date:  2016-04-04       Impact factor: 4.418

Review 5.  Rapamycin passes the torch: a new generation of mTOR inhibitors.

Authors:  Don Benjamin; Marco Colombi; Christoph Moroni; Michael N Hall
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

Review 6.  Fighting neurodegeneration with rapamycin: mechanistic insights.

Authors:  Jordi Bové; Marta Martínez-Vicente; Miquel Vila
Journal:  Nat Rev Neurosci       Date:  2011-07-20       Impact factor: 34.870

7.  Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.

Authors:  Denise Rageot; Thomas Bohnacker; Anna Melone; Jean-Baptiste Langlois; Chiara Borsari; Petra Hillmann; Alexander M Sele; Florent Beaufils; Marketa Zvelebil; Paul Hebeisen; Wolfgang Löscher; John Burke; Doriano Fabbro; Matthias P Wymann
Journal:  J Med Chem       Date:  2018-11-14       Impact factor: 7.446

8.  The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy.

Authors:  Claudia Brandt; Petra Hillmann; Andreas Noack; Kerstin Römermann; Leon A Öhler; Denise Rageot; Florent Beaufils; Anna Melone; Alexander M Sele; Matthias P Wymann; Doriano Fabbro; Wolfgang Löscher
Journal:  Neuropharmacology       Date:  2018-08-03       Impact factor: 5.250

9.  Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.

Authors:  Vanessa S Rodrik-Outmezguine; Masanori Okaniwa; Zhan Yao; Chris J Novotny; Claire McWhirter; Arpitha Banaji; Helen Won; Wai Wong; Mike Berger; Elisa de Stanchina; Derek G Barratt; Sabina Cosulich; Teresa Klinowska; Neal Rosen; Kevan M Shokat
Journal:  Nature       Date:  2016-05-18       Impact factor: 49.962

10.  Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice.

Authors:  Yann Ehinger; Ziyang Zhang; Khanhky Phamluong; Drishti Soneja; Kevan M Shokat; Dorit Ron
Journal:  Nat Commun       Date:  2021-07-27       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.